Edgewise has shared a community letter announcing that six sites are now open for enrollment for the Canyon trial for individuals living with Becker muscular dystrophy. Canyon is a Phase 2 trial of EDG-5506, a myosin modulator, evaluating safety, tolerability, biomarkers of muscle damage, and changes in functional measures in adolescents and men with Becker.

Edgewise will be joining PPMD for a community webinar tomorrow, October 19th at 1 PM ET to discuss the clinical development program for EDG-5506 in both Becker and Duchenne. Register to join us.